^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Alkylating agent

    Related drugs:
    1d
    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov)
    P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    1d
    B7-H3.CD28Z.CART in CNS Neoplasms (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Robbie Majzner
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV
    3d
    EMERGE 101: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Jazz Pharmaceuticals | Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Dec 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Zepzelca (lurbinectedin)
    3d
    ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov)
    P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033
    Trial completion date • Trial primary completion date • HEOR
    |
    temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)
    3d
    Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=38 --> 12
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • etoposide IV
    3d
    Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma. (PubMed, Blood Adv)
    Conditioning was based on total body irradiation (TBI) in 30 patients and on chemotherapy in 27 patients, mainly with reduced-toxicity conditioning (RTC; Treosulfan, Fludarabine, and Thiotepa). Our data support the use of TBI-free conditioning and suggest improved outcomes with unrelated donors receiving ATLG prophylaxis. NCT00317408.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    fludarabine IV • thiotepa • Grafapex (treosulfan)
    3d
    Modulation of AMPK/SIRT1 signaling by piribedil attenuates cyclophosphamide-induced nephrotoxicity via PI3K/Akt, MAPKs, and TLR4/NLRP3 pathways with regulation of KIM-1/NGAL. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Piribedil effectively protects against CP-induced nephrotoxicity by modulating AMPK/SIRT1 and related oxidative and inflammatory pathways, supporting its potential use in drug-induced kidney injury.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • KIM1 (Kidney injury molecule 1) • TLR4 (Toll Like Receptor 4) • LCN2 (Lipocalin-2) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    cyclophosphamide
    4d
    NRG-BN011: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (clinicaltrials.gov)
    P3, N=306, Suspended, NRG Oncology | Recruiting --> Suspended
    Trial suspension
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH1 R132
    |
    temozolomide • lomustine
    4d
    Lacosamide prevents cyclophosphamide-induced testicular dysfunction via inhibition of NF-κB/IL-6/STAT-3 and JNK1/Caspase-3 axes with AR and HO-1 preservation: in vivo and in silico evidence. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    LCM treatment effectively mitigated these deleterious effects through multi-target protective mechanisms including c-jun N-terminal kinase 1(JNK1)-mediated apoptosis inhibition, HO-1 upregulation, IL-6/ signal transducer and activator of transcription 3 (STAT-3) signaling suppression, prevention of p-JNK1/STAT-3 crosstalk, and AR preservation. This study establishes LCM's multi-target protective efficacy, supporting its potential as a safer antiepileptic alternative providing dual benefits of seizure control and reproductive preservation during chemotherapy.
    Preclinical • Journal • IO biomarker
    |
    AR (Androgen receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    cyclophosphamide
    4d
    Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease. (PubMed, Blood Adv)
    The use of non-treosulfan-based myeloablative conditioning (MAC) regimens increased the risk of endothelial complications compared to reduced-intensity conditioning (RIC) (HR, 4.9; 95% CI, 1.1-22.0; P=0.040), whereas outcomes with treosulfan-based MAC were comparable to RIC. In summary, allogeneic HSCT is a viable curative strategy for ED when performed before transformation to an aggressive malignancy i.e. myelodysplasia with excess blasts or acute myeloid leukemia. However, the elevated incidence of endothelial toxicity highlights the importance of optimizing conditioning intensity and enhancing peritransplant monitoring in this population.
    Clinical • Journal
    |
    TP53 (Tumor protein P53) • ERCC6 (Excision repair cross-complementation group 6)
    |
    TP53 mutation
    |
    Grafapex (treosulfan)
    4d
    Collision tumor of endometrial hepatoid adenocarcinoma and endometrial stromal sarcoma: a rare case and literature review. (PubMed, Front Oncol)
    In this context, the CAP regimen-comprising cyclophosphamide, adriamycin, and cisplatin-has demonstrated superior overall efficacy. Moreover, these tumors seem to be relatively resistant to radiation therapy.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide
    6d
    KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Corregene Biotechnology Co., Ltd | Not yet recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12
    |
    cyclophosphamide • fludarabine IV